GlassScriptPhysician profile
Andrea M Dunlap
NPI 1073554663
$19,016.47
in general payments reported to CMS, 2019-2025
31 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,568 · 2022: $4,894 · 2023: $5,239 · 2024: $4,862 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,291.83 |
| Education | $262.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,333.10 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,146.16 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $1,762.40 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,425.37 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Uswm, LLC | $1,224.75 | 2021-2024 | Lucemyra, Zimhi |
| Otsuka America Pharmaceutical, INC. | $1,063.10 | 2021-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $1,023.97 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $918.26 | 2021-2025 | Sublocade, Perseris |
| Supernus Pharmaceuticals, INC. | $916.74 | 2021-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $811.79 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $802.90 | 2021-2024 | Caplyta |
| Lundbeck LLC | $705.60 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $573.25 | 2021-2024 | Trintellix |
| Almatica Pharma LLC | $551.91 | 2022-2024 | Loreev Xr |
| Corium, LLC | $422.28 | 2022-2024 | Azstarys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $410.20 | 2021-2023 | Belsomra, Verquvo |
| Bausch Health US, LLC | $372.33 | 2021-2025 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $304.52 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $235.25 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $222.23 | 2021 | |
| Eisai INC. | $152.24 | 2021-2022 | |
| Tris Pharma INC | $136.45 | 2024 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $126.35 | 2021-2024 | |
| Ironshore Pharmaceuticals INC. | $100.68 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $92.90 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $45.27 | 2021 | |
| Collegium Pharmaceutical, INC. | $35.41 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $33.11 | 2022 | |
| Noven Therapeutics, LLC | $32.33 | 2021-2024 | Secuado, Xelstrym |
| Pear Therapeutics (US), INC. | $19.02 | 2021 | |
| Hikma Pharmaceuticals USA | $16.60 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Dunlap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.